HIV-tuberculosis coinfection: Difference between revisions

From IDWiki
()
No edit summary
Line 10: Line 10:
*[[Rifampin]] is a core antimicrobial for tuberculosis and should be given priority in drug-drug interactions
*[[Rifampin]] is a core antimicrobial for tuberculosis and should be given priority in drug-drug interactions
*NRTIs do not require any adjustment, INSTIs and NRTIs often need dose adjustment, and PIs are usually contraindicated
*NRTIs do not require any adjustment, INSTIs and NRTIs often need dose adjustment, and PIs are usually contraindicated
*Regimens that do not require dose adjustment:
*Regimens that minimize drug-drug interactions:
**[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]]
**[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]]
**[[tenofovir disoproxil fumarate]]/[[emtricitabine]] + [[efavirenz]]
**[[tenofovir disoproxil fumarate]]/[[emtricitabine]] + double [[raltegravir]]
**[[Abacavir]]/[[lamivudine]] with BID [[dolutegravir]]
**[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]]
**[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]]
*Timing
*Timing

Revision as of 01:22, 4 September 2020

Management

Latent Tuberculosis Infection

Active Tuberculosis